Indegene Ltd

- The transcript on page 17 does not mention any current or future fundraising plans through debt or equity. - No references to raising capital or funding rounds were discussed during the Q&A or closing remarks. - Cash and investments remain strong with approximately USD 210 million as of September 30, 2025. - The company focused on recent acquisitions (BioPharm and WARN & CO) completed in October 2025, funded through existing resources. - Financial commentary emphasizes managing margins and investments internally without indicating external fundraising. - Overall, no explicit plans for new debt or equity fundraising were disclosed in this call.

- Indegene is making strategic investments ahead of the curve to capitalize on market opportunities over the next 6 to 8 quarters, which will cause near-term EBITDA margin compression of about 1.5%. - Recent acquisitions: - BioPharm, a U.S.-based omnichannel marketing company, acquired in October 2025 to expand capabilities in downstream omnichannel campaign execution and scale globally. - WARN & CO, a U.K.-based boutique consulting firm specializing in change management, transformation consulting, and digital/technology for pharma, also acquired in October 2025. - Investments include: - Increased marketing expenses, including the IDS 2025 event in Philadelphia. - Higher technology costs due to infrastructure, cloud subscriptions, and GenAI related expenses. - Talent acquisition and upskilling for an AI-first world. - Integration of acquisitions is underway with support functions transitioning over two quarters and business operations over six quarters.

- Indegene sees the market opening up with stronger demand and quality of engagements compared to 12-18 months ago. - The uncertain pharma environment is stabilizing, leading to companies progressing with regular plans. - Pharma companies are focusing on efficiency and digital initiatives, including AI, creating growth opportunities. - The Tectonic platform has a growing pipeline with multiple paid customers and potential deal closures expected by year-end. - Brand Activation segment has a healthy pipeline expected to convert in coming quarters, helping to offset past project deferrals. - Headcount is expected to grow but at a lower rate than revenue growth, reflecting higher productivity. - Overall, the company anticipates growth rates higher than the previous year and the start of the current year, reflecting a positive market outlook. - No specific guidance is given, but the company is optimistic about near- to mid-term growth given current opportunities.

- Indegene sees the challenging pharma industry environment stabilizing, with reduced uncertainty and stronger demand compared to 12-18 months ago. - Growth rates are expected to improve in coming quarters versus the previous year and start of this year, driven by expanding digital initiatives and AI adoption. - The company does not provide explicit guidance but expresses optimism on pipeline and deal closures, particularly from Tectonic and Brand Activation segments. - Margin compression (~1-1.5%) is anticipated near term due to investments, but margins are expected to recover over 6-8 quarters via productivity improvements and pricing strategies. - Headcount will grow but at a slower rate than revenue, supporting efficiency gains and higher revenue per employee. - Integration of acquisitions (BioPharm, WARN & CO) aims to drive long-term growth though integration takes several quarters. - Overall, Indegene expects higher growth and eventual margin recovery leading to improvement in earnings and EPS over the medium term.

- Tectonic segment has built a very promising and fast-growing pipeline with expectations to close much of it by end of December 2025 or early January 2026 due to customers' Jan-Dec planning cycles. - Two new paying customers were converted from unpaid pilots in the current quarter, indicating expanding orderbook. - Brand Activation segment has a healthy pipeline despite some project deferrals; significant ramp-up expected in Q3 2025 to offset degrowth from closed projects. - Strong client pipelines across top enterprise commercial and medical segments. - Largest customer shows a strong pipeline and is expected to grow in near to midterm. - Overall, market demand and quality of client engagements have strengthened compared to 12-18 months ago, with growing interest in digital and AI-driven initiatives expanding future opportunities.